Biofrontera's Ameluz® PDT Gains FDA Acceptance for Basal Cell Carcinoma Expansion

Event summary

  • FDA accepted Biofrontera's sNDA for Ameluz® in superficial Basal Cell Carcinoma (sBCC), setting a PDUFA target action date of September 28, 2026.
  • Ameluz® would be the first PDT photosensitizer indicated for sBCC if approved, expanding beyond its current use in actinic keratosis.
  • sBCC affects 360,000–900,000 annual cases in the U.S., representing 10–25% of all basal cell carcinoma diagnoses.
  • Biofrontera's PDT platform combines Ameluz®'s nanoemulsion technology with red-light illumination for deeper tissue penetration.

The big picture

Biofrontera’s FDA filing acceptance marks a strategic pivot from actinic keratosis to non-melanoma skin cancer, targeting a larger and more lucrative market. The approval, if granted, would validate the company’s PDT technology, positioning it as a key player in dermatological oncology. With 3.6 million basal cell carcinoma cases annually in the U.S., the potential market opportunity is substantial, though competition from established surgical methods remains a hurdle.

What we're watching

Regulatory Success
Whether Biofrontera can secure FDA approval by the September 28, 2026 PDUFA date, clearing the path for Ameluz®'s first indication in cancer treatment.
Market Expansion
The pace at which Biofrontera can penetrate the sBCC market, competing with surgical and destructive treatment alternatives.
Technology Validation
How the approval of Ameluz® for sBCC will reinforce the clinical utility of Biofrontera’s PDT platform in dermatology.